Recent News

• Acquires 80% stake in Dubai-based Advanced Care Oncology Center  
• Announces plan to launch ACOC-branded radiation oncology centers across GCC 

Abu Dhabi, UAE, February 18, 2025: Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare provider in the MENA region, listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), has announced its plan to establish the leading radiation oncology network in the GCC, following its successful acquisition of an 80% stake in the Dubai-based Advanced Care Oncology Center (ACOC), renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services.This transformative initiative aims to redefine cancer care delivery in the region, leveraging ACOC’s expertise to build a network that ensures accessible and advanced oncology treatment. 

Oncology Global & GCC Landscape 

Globally, cancer cases are projected to increase significantly, driven by aging populations and lifestyle changes. According to the World Health Organization, annual global cancer diagnoses are expected to rise from 20 million in 2024 to over 30 million by 2040, highlighting the growing global burden of cancer. 

In the GCC, the oncology landscape presents both challenges and opportunities. Cancer cases in the region are anticipated to grow by approximately 50% over the next two decades, driven by similar demographic and lifestyle trends. However, the region faces a critical shortage of cancer care infrastructure to manage the growing cases, leading to substantial unmet demand for specialized oncology services. This highlights the immense potential for Burjeel Holdings to expand its oncology platform, ensuring timely and effective cancer treatments to meet regional healthcare needs. 

Additionally, the growing adoption of advanced oncology solutions, such as radiation therapy, robotic surgical oncology, and precision medicine, demonstrates a clear trend towards innovative and specialized care pathways in the GCC. 

Driving Cancer Care Leadership in the GCC 

The planned ACOC-branded network aims to strategically improve oncology access  in underserved markets across the GCC.  

• Enhance Accessibility: The stand-alone ACOC centers will serve as trusted hubs for radiation therapy, expanding patient access to specialized care in underserved regions across the UAE and the GCC. 
• Integrate Advanced Technology: Each center will be equipped with cutting-edge technologies, including state-of-the-art LINAC systems, AI-driven radiation planning, and precision imaging tools.  
• Streamline Referrals: By offering focused and dedicated radiation therapy services, ACOC-branded centers will establish a robust platform for referrals from a broad network of healthcare providers. 
• Support Burjeel Cancer Institute: The network will support Burjeel Cancer Institute (BCI), the Group’s hub for advanced cancer treatments. Patients requiring surgical oncology, immunotherapy, robotic surgery, and bone marrow transplants will benefit from a smooth and integrated transition to the Group’s comprehensive, cutting-edge care. 
• Foster Research & Innovation: Leveraging the Oracle Health EMR implementation for its diverse patient base, the network will drive medical research and data-driven innovations, further solidifying Burjeel’s leadership in preventive oncology and precision medicine. 

Further information, including details of the expansion plan, will be disclosed in due course. 

Burjeel Cancer Institute: Anchor of Burjeel’s Oncology Platform 

This acquisition is a strategic fit for the Group’s growing oncology platform, anchored by BCI,  one of the UAE’s largest cancer care networks. With facilities spanning Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai, the Group delivers integrated and comprehensive oncology services. These include medical oncology, radiation therapy, robotic surgical oncology, bone marrow transplants, and palliative care. The integration of ACOC into Burjeel’s ecosystem will enhance synergy between stand-alone radiation oncology centers. This structure ensures a streamlined and efficient care pathway, where referrals to the Group are directed toward highly specialized treatments, complementing the network’s broader accessibility and outreach.    

Mr. John Sunil, Group CEO of Burjeel Holdings, said: “Our vision is to establish a comprehensive and advanced oncology network in the GCC, addressing unmet needs in specialized cancer care. By building on ACOC’s legacy of excellence, we will bring accessible, high-quality radiation oncology services closer to patients, significantly enhancing cancer care outcomes across the region. This network will not only support early intervention and treatment but will also connect seamlessly with the Burjeel Cancer Institute for advanced therapies.” 

ACOC Transaction Highlights 

• Value Transaction: Burjeel has acquired an 80% equity stake in ACOC for AED 92 million on a cash-free, debt-free basis, with an option to acquire the remaining stake. ACOC recorded revenue of AED 64 million in 2024. 
• Continuity of Leadership: ACOC’s Founder and CEO, Bashir Abou Reslan, retains a 10% stake and continues to lead the center’s operations, ensuring continuity and excellence in patient care. The remaining 10% continues to be held by Raphael Khlat Middle East FZCO, an existing shareholder. 

About Burjeel Holdings  

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 100 assets across the UAE, Oman, and Saudi Arabia, including 19 hospitals, 29 medical centers, 29 physiotherapy and wellness centers, 15 pharmacies, and other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel. 

About Advanced Care Oncology Center 

Established in 2017, ACOC is a trusted provider of integrated cancer care services in Dubai. The center is renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services. ACOC’s commitment to clinical excellence is underscored by its accreditations, including the Gold Accreditation from Accreditation Canada, awarded in August 2021. It is the only facility in the UAE to hold PET/CT EARL Accreditation from the European Association of Nuclear Medicine (EANM). Additionally, ACOC received the Certificate of Medical Prescription Audit from Bienzobas in Spain in October 2021, demonstrating compliance with European regulatory standards such as EMA guidelines and international protocols from NICE and NCCN. 

Contacts 

Investor Relations:  Sergei Levitskii  Director of Investor Relations  ir@burjeelholdings.com  M: +971 50 380 2383

Media:  M. Unnikrishnan  Corporate Communications Officer  krish@burjeelholdings.com  M: +971 50 427 5895

The Orthopedic Residency and Hematology-Oncology Fellowship programs will equip physicians with the expertise needed to meet global healthcare standards

Abu Dhabi, February 15, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has achieved a significant milestone in healthcare education by receiving accreditation from the National Institute for Health Specialties (NIHS), a prestigious accreditation program in the UAE. The two specialized medical training programs—Orthopedic Residency and Hematology-Oncology Fellowship—have secured this accreditation. The Hematology-Oncology Fellowship marks a milestone for Burjeel Holdings as the first healthcare provider in the UAE to achieve this recognition, while the accreditation for the Orthopedic Residency sets a precedent in Abu Dhabi’s private healthcare sector.

The accreditation was officially conferred by Dr. Mohammed Al Houqani, Secretary General of NIHS during a ceremony attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, H.E. Dr. Rashed Alsuwaidi, the Acting Director General of Healthcare Regulatory at Department of Health – Abu Dhabi, Mr. John Sunil, Group CEO of Burjeel Holdings, and Mr. Safeer Ahamed, Group Co-CEO of Burjeel Holdings.

Dr. Mohammed Al Houqani praised Burjeel Holdings’ role in advancing medical education, highlighting its significant contributions to training the healthcare workforce and equipping them with the highest global standards. He emphasized the Group’s efforts in creating an ideal training environment based on best medical practices, which will strengthen the healthcare sector with specialized and qualified physicians capable of delivering high-quality medical services for healthcare challenges.

Speaking about this achievement, Dr. Tahani Al Qadiri, Group Director of Emiratization and Academics at Burjeel Holdings, said that this accreditation is a testament to Burjeel’s commitment to raising the next generation of specialized healthcare professionals in the region. “This milestone not only strengthens our position as a leader in private-sector medical education but also contributes significantly to Abu Dhabi’s healthcare ecosystem by nurturing highly skilled specialists,” she added.

These specialized programs will provide rigorous, hands-on training for medical residents and fellows, equipping them with the expertise required to meet global healthcare standards. The Orthopedic Residency Program will prepare aspiring trainees with comprehensive clinical experience, while the Hematology-Oncology Fellowship Program will cultivate highly specialized expertise in cancer care.

According to Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, the initiative will contribute to better patient outcomes. “By establishing the first accredited Hematology-Oncology Fellowship Program in the private sector in the country, we are creating a structured pathway for developing highly skilled oncologists who will play a crucial role in enhancing cancer care in the region,” he said.

Dr. Mohamed Muath ADI, Consultant Orthopedic Surgeon at Burjeel Medical City (BMC) and Program Director of the Orthopedic Residency Program, said that this milestone will enhance the quality of orthopedic education and training in the region, further elevating the standard of orthopedic care in the UAE.

This accreditation, aligning with the UAE’s strategic vision to advance the healthcare sector, reflects Burjeel’s commitment to advancing medical education, and positioning Abu Dhabi as a hub for world-class medical training.

The new center reflects Burjeel’s ongoing commitment to expanding its services and meeting the growing healthcare needs of the community with integrated, world-class medical care

Al Ain, February 11, 2025 – Burjeel Cancer Institute (BCI), the largest cancer care network in the UAE, has expanded its reach by opening a new center at Burjeel Hospital Al Ain. This strategic expansion reinforces Burjeel Holdings’ commitment to providing world-class oncology services across the country, ensuring advanced cancer care is accessible to more patients.

The inauguration ceremony was attended by Mr. John Sunil, Group CEO of Burjeel Holdings, along with distinguished guests from the Al Ain Traffic Police, Abu Dhabi Agriculture and Food Safety Authority, and Al Ain Civil Defense.

BCI, the oncology arm of Burjeel Holdings, operates from its flagship facility, Burjeel Medical City in Abu Dhabi. At the forefront of oncology treatment and research, BCI brings cutting-edge therapies and a multidisciplinary approach to patient care. The new center at Burjeel Hospital Al Ain reflects its commitment to expanding services and meeting the community’s growing healthcare needs with integrated, world-class medical care.

The newly opened center in Al Ain offers a full spectrum of oncology services, including expert consultations, state-of-the-art diagnostic capabilities and specialized treatments such as chemotherapy, immunotherapy, and targeted therapies. The institute also provides comprehensive surgical oncology services, performed by a team of leading specialists utilizing the latest medical technologies to ensure precision and efficiency. To enhance patient comfort and privacy, the facility features dedicated chemotherapy suites, creating a supportive and personalized treatment environment. The seamless integration of these services ensures that patients receive a holistic care experience, from diagnosis through recovery.

Professor Humaid bin Harmal Al Shamsi, Consultant Oncologist and CEO of Burjeel Cancer Institute, emphasized the significance of this expansion.

“The opening of BCI in Al Ain reflects our commitment to expanding oncology services and making specialized cancer care more accessible across the UAE. Our goal is to bring high-quality, patient-centered treatment closer to those in need, ensuring that individuals in Al Ain have access to the latest advancements in cancer care without the need to travel far.”

“At BCI, we prioritize a seamless patient journey from diagnosis to treatment and recovery, with a multidisciplinary approach that enhances outcomes and quality of life. To further ease access to care, we welcome patients for consultations without requiring prior appointments, reinforcing our mission to provide an integrated and patient-first experience,” he said.

Dr. Aysha Almahri, CEO - Al Ain Region, Burjeel Holdings, highlighted the institute’s impact on cancer care in the region.

“At Burjeel, we recognize that the foundation of a thriving society lies in the health and well-being of its people. Cancer care is a top priority, and this expansion ensures that more patients have access to cutting-edge therapies, reducing the need for medical travel. With the establishment of BCI in Al Ain, we reaffirm our commitment to providing world-class oncology treatments to patients across the UAE.”

With the launch of the new center in Al Ain, Burjeel Holdings continues to redefine oncology care by offering patients state-of-the-art treatment options, further solidifying the UAE’s position as a regional leader in specialized cancer care.

The lab is dedicated to the comprehensive diagnosis, treatment, and rehabilitation of balance and vertigo disorders

Abu Dhabi: Burjeel Medical City (BMC), the flagship facility under Burjeel Holdings, has unveiled a state-of-the-art Balance Lab within the Burjeel ENT Head & Neck Institute. This new facility is dedicated to the comprehensive diagnosis, treatment, and rehabilitation of balance and vertigo disorders, further strengthening BMC’s advanced offerings in otolaryngology (ear, nose, throat) and head & neck surgery.

The Balance Lab was officially opened in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. John Sunil, Group CEO of Burjeel Holdings, alongside Dr. Mujtaba Ali Khan, CEO of BMC, and other senior officials.

The Balance Lab was officially opened in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. John Sunil, Group CEO of Burjeel Holdings, alongside Dr. Mujtaba Ali Khan, CEO of BMC, and other senior officials.

Specialized Focus on Balance and Vertigo Disorders

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Designed to address a wide range of balance and vertigo conditions affecting all age groups, the Balance Lab utilizes a structured testing protocol to accurately diagnose and quantify the underlying causes of dizziness and imbalance. These conditions can result from various factors, including inner ear disorders, neurological issues, strokes, muscle weaknesses, and peripheral neuropathy.

Advanced Hearing Aid Services

In addition to balance services, the institute has introduced a hearing aid booth equipped with advanced technologies, offering patients a range of hearing aids and comprehensive services including fitting, calibration, programming, troubleshooting, ear molds, swim plugs, and tinnitus masking devices. This addition enhances the clinic’s ability to provide personalized and efficient hearing care.

The introduction of advanced technologies and services in the balance lab and hearing aid booth is expected to bring significant improvements in patient care across several dimensions, including diagnosis accuracy, treatment outcomes, patient engagement, and overall patient experience.